Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

Combination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. La, R. Fujikawa, D. M. Janzen, M. Nunez, L. Bainvoll, L. Hwang, K. Faull, G. Lawson, S. Memarzadeh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7a7a5d26d3d140b79e1df58bdb310f23
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a7a5d26d3d140b79e1df58bdb310f23
record_format	dspace
spelling	oai:doaj.org-article:7a7a5d26d3d140b79e1df58bdb310f232021-12-02T16:05:42ZBirinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy10.1038/s41698-017-0008-z2397-768Xhttps://doaj.org/article/7a7a5d26d3d140b79e1df58bdb310f232017-04-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0008-zhttps://doaj.org/toc/2397-768XCombination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent initial response rates, tumor growth recurs in most patients as they develop resistance to therapy. Sanaz Memarzadeh and colleagues at the University of California, Los Angeles, show that the addition of birinapant to carboplatin eliminates platinum-resistant ovarian cancer cells by degrading the cell death-inhibiting proteins cIAP1 and cIAP2. Carboplatin and birinapant co-therapy restored the efficacy of the chemotherapeutic in human tumor samples and in mice with platinum-resistant tumors. Furthermore, the levels of cIAP protein in the resistant cells were predictive of the therapeutic response. These findings will help to select clinical trial patients that are most likely to benefit from this combination therapy.V. LaR. FujikawaD. M. JanzenM. NunezL. BainvollL. HwangK. FaullG. LawsonS. MemarzadehNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
description	Combination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent initial response rates, tumor growth recurs in most patients as they develop resistance to therapy. Sanaz Memarzadeh and colleagues at the University of California, Los Angeles, show that the addition of birinapant to carboplatin eliminates platinum-resistant ovarian cancer cells by degrading the cell death-inhibiting proteins cIAP1 and cIAP2. Carboplatin and birinapant co-therapy restored the efficacy of the chemotherapeutic in human tumor samples and in mice with platinum-resistant tumors. Furthermore, the levels of cIAP protein in the resistant cells were predictive of the therapeutic response. These findings will help to select clinical trial patients that are most likely to benefit from this combination therapy.
format	article
author	V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh
author_facet	V. La R. Fujikawa D. M. Janzen M. Nunez L. Bainvoll L. Hwang K. Faull G. Lawson S. Memarzadeh
author_sort	V. La
title	Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_short	Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_full	Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_fullStr	Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_full_unstemmed	Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_sort	birinapant sensitizes platinum-resistant carcinomas with high levels of ciap to carboplatin therapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/7a7a5d26d3d140b79e1df58bdb310f23
work_keys_str_mv	AT vla birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT rfujikawa birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT dmjanzen birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT mnunez birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT lbainvoll birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT lhwang birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT kfaull birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT glawson birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy AT smemarzadeh birinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
_version_	1718385156953210880

Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

Ejemplares similares